PTSM: Pharmaceutical Technology Sourcing and Management
CDMO for semi-solid and liquid manufacturing realigns operations at Texas facility.
DPT Laboratories, a contract development and manufacturing organization, implemented a new operational strategy to enhance operations at its San Antonio, Texas facility. The company realigned and augmented resources to support high-speed bottle production, aerosols/foams filling and packaging, and traditional semi-solids and liquids production. One of three DPT Centers of Excellence, the San Antonio facility was purpose-built to support semi-solid and liquid development and manufacturing solutions. This new strategy represents the next step for the company’s existing operational platform, the company said in a July 8, 2015 press release.
“We focused on prioritizing the technical expertise and resources we already have, adding new resources where necessary to create more specialized work centers,” said Lyle Flom, vice-president and general manager of DPT’s San Antonio site operations, in the release. “With these structural changes, our teams will be able to focus their technical expertise to improve operational efficiencies and enhance our already strong quality record at this site. This is an evolution of our Center of Excellence strategy in the semi-solid and liquid space and supports our strategic commitment to continuously improve our manufacturing execution and regulatory/compliance environments.”
Source: DPT Laboratories
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.